Redefining Omalizumab Discontinuation in Chronic Spontaneous Urticaria: The Value of Optimization and Predictive Factors of Relapse. A 52-Week Multicenter Study
Optimization seems to reduce the relapse rate after discontinuation. The most relevant factors for recurrence are associated with the duration of treatment at different doses of omalizumab, along with the baseline CRP and total IgE levels. To minimize relapse after suspension, a 12-month treatment regimen at 300mg/4 weeks followed by an 18-month dose tapering is proposed.
Authors
- Joan Ceravalls (ORCID: https://orcid.org/0000-0003-0720-9280)
- Gemma Melé‐Ninot (ORCID: https://orcid.org/0000-0003-0365-0634)
- Natalia Fernández Chico
- Jorge Spertino
- Esteban Carlos Serra (ORCID: https://orcid.org/0000-0001-5986-7459)
- Carola Baliu‐Piqué
- Montserrat Bonfill‐Ortí (ORCID: https://orcid.org/0000-0002-3183-7538)
- V. Expósito‐Serrano (ORCID: https://orcid.org/0000-0002-9256-1723)
- Paula Ribó (ORCID: https://orcid.org/0000-0002-9129-5347)
- Ana Maria Giménez‐Arnau (ORCID: https://orcid.org/0000-0001-5434-7753)
- Isabel Bielsa (ORCID: https://orcid.org/0000-0001-7978-6111)
- A. Moya
- B Mascaró-Hereza
Institutions
- Universitat Autònoma de Barcelona (ES)
- Universitat Pompeu Fabra (ES)
- Hospital de Sant Pau (ES)
- Bellvitge University Hospital (ES)
- Hospital Quirónsalud Barcelona (ES)
- Hospital Clínic de Barcelona (ES)
- Corporació Sanitària Parc Taulí (ES)
- Hospital d'Igualada (ES)
- Hospital de Sabadell (ES)
- Hospital Universitari Sagrat Cor (ES)
- Hospital Universitari Germans Trias i Pujol (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Actas Dermo-Sifiliográficas
- Published
- 2025-02-28
- DOI
- https://doi.org/10.1016/j.ad.2024.08.014
- Citations
- 9
- Primary Topic
- Urticaria and Related Conditions
- Type
- article
- Field-Weighted Citation Impact
- 15.01